AEON Biopharma
AEON
22 hedge funds and large institutions have $1.67M invested in AEON Biopharma in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 3 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
51% more capital invested
Capital invested by funds: $1.1M → $1.67M (+$564K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
8.92% more ownership
Funds ownership: 11.72% → 20.64% (+8.9%)
5% more funds holding
Funds holding: 21 → 22 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$941K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$38K |
| 3 |
LNWTC
Laird Norton Wetherby Trust Company
Seattle,
Washington
|
+$14K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$12.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StoneX Group
New York
|
-$14.2K |
| 2 |
Jane Street
New York
|
-$8.43K |
| 3 |
Barclays
London,
United Kingdom
|
-$17 |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$1 |
AEON Hedge Fund Activity: Q4 2025 in Review
22 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2025, worth a combined $1.67M — up 51% from $1.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AEON positions and 3 closed out — a net gain of 1 holder — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Dauntless Investment Group, adding an estimated $941K. The largest seller was StoneX Group, exiting entirely with an estimated $14.2K sold.
- 22 institutional investors held AEON Biopharma (AEON) as of Q4 2025, up from 21 in Q3 2025.
- Funds reported $1.67M of AEON Biopharma stock for Q4 2025, up 51% quarter-over-quarter.
- 4 funds opened new AEON Biopharma positions in Q4 2025 and 3 closed out, a net change of +1 holder.
- The largest AEON Biopharma buyer in Q4 2025 was Dauntless Investment Group, an estimated $941K added.
- The largest AEON Biopharma seller in Q4 2025 was StoneX Group, an estimated $14.2K sold.
Based on aggregated 13F filings for Q4 2025.